Correct answer: C — Rifampin, isoniazid, pyrazinamide, and ethambutol
- ARifampin and isoniazid
- BBedaquiline, linezolid, and pretomanid
- CRifampin, isoniazid, pyrazinamide, and ethambutol✓
- DIsoniazid monotherapy
- ERifampin, isoniazid, and pyrazinamide
Why Rifampin, isoniazid, pyrazinamide, and ethambutol is correct
- Active drug-susceptible pulmonary tuberculosis requires the standard first-line regimen: a 2-month intensive phase of rifampin, isoniazid, pyrazinamide, and ethambutol (RIPE), followed by a 4-month continuation phase of rifampin and isoniazid.
- Four drugs are used initially to prevent emergence of resistance and rapidly reduce bacillary load.
Why the others are wrong
- Bedaquiline, linezolid, and pretomanid — the BPaL regimen is reserved for multidrug- or extensively drug-resistant TB, not drug-susceptible disease (wrong-resistance-tier).
- Rifampin and isoniazid — this two-drug combination is the continuation phase used after the intensive phase, inadequate as initial therapy (right-drugs-wrong-phase).
- Isoniazid monotherapy — the regimen for latent TB infection without active disease; using it here would select for resistance (confused-with latent TB).
- Rifampin, isoniazid, and pyrazinamide — dropping ethambutol is tempting because rifampin resistance was not detected, but ethambutol is stopped only after susceptibility testing confirms the isolate is susceptible to both isoniazid and rifampin; a NAAT that reports only rifampin resistance does not exclude isoniazid resistance, the most common first-line drug resistance (premature-de-escalation).
Additional high-yield points
- Directly observed therapy is recommended to ensure adherence.